Northwestern University Human Resources
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1851-01-28
- Employees
- 5K
- Market Cap
- -
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 32
- Registration Number
- NCT06242834
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Combination Intervention to Enhance Treatment Engagement and Viral Suppression Among Sexual and Gender Minority Youth in Nigeria
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 100
- Registration Number
- NCT06190613
- Locations
- 🇳🇬
University of Ibadan, Ibadan, Nigeria
Randomized Controlled Trial of Project Body Neutrality
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 250
- Registration Number
- NCT06172452
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 20
- Registration Number
- NCT06169280
Far Red Light to Improve Functioning in PAD
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 32
- Registration Number
- NCT06165016
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 30
- Registration Number
- NCT06164275
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Cadence Health - CDH, Warrenville, Illinois, United States
Evaluation of Neuroma Perfusion With Indocyanine Green Fluorescence Angiography
Phase 4
- Conditions
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 25
- Registration Number
- NCT06164392
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Sleep Length and Euploid Embryo Transfer Prospective Study
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 150
- Registration Number
- NCT06139757
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
Surgeon Perception of Gastric Decompression at Time of Gynecologic Laparoscopy
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 150
- Registration Number
- NCT06137976
- Locations
- 🇺🇸
Prentice Women'S Hospital, Chicago, Illinois, United States
🇺🇸259 E Erie - Northwestern, Chicago, Illinois, United States
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT06137651
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
© Copyright 2024. All Rights Reserved by MedPath